Rheumatoid arthritis and the era of biologic therapy
Rheumatoid arthritis and the era of biologic therapy
复制标题
DOI：
10.1007/s10787-012-0123-y
复制
发表时间：
2012-04-01
影响因子：
5.8
通讯作者：
Oestoer, Andrew J. K.
中科院分区：
文献类型：
--
作者：
Malaviya, Anshuman P.;Oestoer, Andrew J. K.
自十多年前引入临床实践以来，生物疾病修饰抗风湿药物已经改变了类风湿关节炎（RA）的管理。在大规模临床试验之后，许多具有不同作用机制的生物制剂已获准用于治疗这种疾病。在这篇综述中，我们将总结目前生物治疗类风湿性关节炎的证据，重点是它们的疗效和耐受性。此外，我们将对该领域目前的局限性和未满足的需求进行评论，并讨论生物干预的未来。
Biologic disease modifying anti-rheumatic drugs have transformed the management of rheumatoid arthritis (RA) since their introduction into clinical practice over a decade ago. Following large-scale clinical trials, a number of biologics, with different mechanisms of action, have been licensed for the condition. In this review, we will summarise the current evidence for biologic use in RA with an emphasis on their efficacy and tolerability. In addition, we will provide a commentary on the current limitations and unmet needs in this area and discuss the future of biologic intervention.